Skip to main content

Xenon Pharmaceuticals Inc.

XENE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001582313

In the last 90 days, Xenon Pharmaceuticals Inc. insiders filed 0 open-market purchases and 2 sales; 315 institutions reported holding it in 13F filings for Q2 2026, worth $6.10B in total; Duquesne Family Office is the only superinvestor holding it.

Holders of 5% or more of XENE

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Xenon Pharmaceuticals Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of XENE
HolderLatest formStakeChangeFirst filedLatest filingFiling
FMR LLC13G/A10.30%9.96M shares+0.40 ppfrom 9.90%Feb 8, 20215 filingsAug 7, 2026SEC
Avoro Capital Advisors LLC13G/A6.26%5.78M shares–Feb 12, 20212 filingsMay 15, 2026SEC
BlackRock, Inc.13G6.20%4.76M sharesNewJul 17, 20251 filingJul 17, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

17 Schedule 13D and 13G filings on Xenon Pharmaceuticals Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on XENE
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 13, 20264:08 PM ETWellington Management Group LLPand 2 others13G/A1.50%1.43M shares−4.70 ppfrom 6.20%Below 5%Jun 30, 2026SEC
Aug 7, 202611:04 AM ETFMR LLCand 1 other13G/A10.30%9.96M shares+0.40 ppfrom 9.90%Jul 31, 2026SEC
Aug 6, 202610:43 AM ETFMR LLCand 1 other13G/A9.90%9.60M shares−1.60 ppfrom 11.50%Jun 30, 2026SEC
May 15, 202611:23 AM ETJanus Henderson Group PLC13G/A4.50%4.18M shares−0.60 ppfrom 5.10%Below 5%Mar 31, 2026SEC
May 15, 20268:17 AM ETAvoro Capital Advisors LLCand 1 other13G/A6.26%5.78M shares–Mar 31, 2026SEC
May 15, 20267:06 AM ETDriehaus Capital Management LLC13G/A4.87%4.49M shares–Below 5%Dec 31, 2025SEC
Feb 10, 202611:23 AM ETWellington Management Group LLPand 3 others13G6.20%4.76M shares+3.40 ppfrom 2.80%Dec 31, 2025SEC
Nov 14, 202510:29 AM ETJanus Henderson Group PLC13G5.10%3.94M sharesNewSep 30, 2025SEC
Aug 12, 202510:34 AM ETWellington Management Group LLPand 2 others13G/A2.80%2.17M shares–Below 5%Jun 30, 2025SEC
Aug 6, 202512:19 PM ETFMR LLCand 1 other13G/A11.50%8.82M shares+1.20 ppfrom 10.30%Jun 30, 2025SEC
Jul 17, 20257:44 PM ETBlackRock, Inc.13G6.20%4.76M sharesNewJun 30, 2025SEC
Mar 7, 202510:01 AM ETFMR LLCand 1 other13G/A10.30%7.85M shares–Feb 28, 2025SEC
Feb 16, 2021Biotechnology Value Fund L P13G/AOld format–––SEC
Feb 12, 2021OrbiMed Advisors LLC13G/AOld format–––SEC
Feb 12, 2021Avoro Capital Advisors LLC13G/AOld format–––SEC
Feb 11, 2021Adage Capital Partners GP, L.L.C.13G/AOld format–––SEC
Feb 8, 2021FMR LLC13GOld format–New–SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Xenon Pharmaceuticals Inc. shares.

No Form 144 notices for Xenon Pharmaceuticals Inc. are on file.